"Extending this agreement with Wako ensures that PCT testing will continue to be available to as many patients as possible, said Ken Berger, senior vice president of Thermo Fishers specialty diagnostics business, "Earlier diagnosis of sepsis enables dramatic cost-savings for healthcare providers and better treatment of their patients."
Severe sepsis strikes more than 750,000 Americans each year, and between 28 to 50 percent patients die within the first month of diagnosis. Hospital costs to treat severe sepsis in the U.S. are estimated at $16 billion dollars annually. Much of this cost is attributed to misdiagnosis or delayed diagnosis, making faster, more accurate detection a national, if not global, imperative. Research published in Critical Care Medicine showed that each hour of delay in therapy can decrease chances of patient survival by 7.6 percent.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $12 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity™ Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com.
About Wako Pure Chemical Industries, Ltd.
Founded in 1922, Wako Pure Chemical Industries, Ltd. has been engaged in the development and manufacture of high-quality products as a comprehensive reagent manufacturer capable of responding to research needs in cutting-edge areas. At present, we use our unique technological capabilities to focus on three key operational areas, namely, Diagnostic Reagents, Laboratory Chemicals, and Specialty Chemicals to meet the diverse requirements of medical professionals, researchers, and industry. The core competence of Wako Pure Chemical Industries, Ltd. lies in our technological strength which creates innovative products of the highest quality. We provide outstanding quality and exceptional services to countries around the world, through Wako Pure Chemical Industries, Ltd., Wako Chemicals GmbH and Wako Chemicals USA, Inc. Visit www.wako-chem.co.jp.